These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 31586192)

  • 1. The anticipated revision of the grading criteria for adult isocitrate dehydrogenase-mutant diffuse glioma within the neuro-oncology community.
    Komori T
    Neuro Oncol; 2019 Dec; 21(12):1485-1486. PubMed ID: 31586192
    [No Abstract]   [Full Text] [Related]  

  • 2. Updating the grading criteria for adult diffuse gliomas: beyond the WHO2016CNS classification.
    Komori T
    Brain Tumor Pathol; 2020 Jan; 37(1):1-4. PubMed ID: 32060660
    [No Abstract]   [Full Text] [Related]  

  • 3. Mitotic index is (still) important for grading isocitrate dehydrogenase (IDH)-mutant astrocytoma.
    Roberts KF; Dahiya SM
    Neuro Oncol; 2023 Aug; 25(8):1450-1451. PubMed ID: 37097042
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [IDH mutation on glioma].
    Mukasa A
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):937-40. PubMed ID: 21751529
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecular categorisation of gliomas.
    Burki TK
    Lancet Oncol; 2015 Jul; 16(7):e320. PubMed ID: 26095778
    [No Abstract]   [Full Text] [Related]  

  • 7. Diffuse glioma - Rare homozygous IDH point mutation, is it an oncogenetic mechanism?
    Singh A; Gurav M; Dhanavade S; Shetty O; Epari S
    Neuropathology; 2017 Dec; 37(6):582-585. PubMed ID: 28782849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Commentary: Diffuse Isocitrate Dehydrogenase-Mutant Gliomas With Histone H3 Alterations Are Distinguished by Unique Clinical Characteristics, Molecular Expression Profile, and Survival Prognosis.
    Blobner J; Tonn JC
    Neurosurgery; 2023 Oct; 93(4):e92. PubMed ID: 37186882
    [No Abstract]   [Full Text] [Related]  

  • 9. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
    Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
    Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDH1 and IDH2 mutations in gliomas.
    Ducray F; Marie Y; Sanson M
    N Engl J Med; 2009 May; 360(21):2248-9; author reply 2249. PubMed ID: 19469031
    [No Abstract]   [Full Text] [Related]  

  • 11. Glioma IDH1 mutation patterns off the beaten track.
    Pusch S; Sahm F; Meyer J; Mittelbronn M; Hartmann C; von Deimling A
    Neuropathol Appl Neurobiol; 2011 Jun; 37(4):428-30. PubMed ID: 20874727
    [No Abstract]   [Full Text] [Related]  

  • 12. Two Unique Glioma Subtypes Revealed.
    Poh A
    Cancer Discov; 2016 Apr; 6(4):334-5. PubMed ID: 26917670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism, gliomas, and IDH1.
    Smeitink J
    N Engl J Med; 2010 Mar; 362(12):1144-5. PubMed ID: 20335593
    [No Abstract]   [Full Text] [Related]  

  • 14. cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant.
    Louis DN; Giannini C; Capper D; Paulus W; Figarella-Branger D; Lopes MB; Batchelor TT; Cairncross JG; van den Bent M; Wick W; Wesseling P
    Acta Neuropathol; 2018 Apr; 135(4):639-642. PubMed ID: 29497819
    [No Abstract]   [Full Text] [Related]  

  • 15. Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma.
    Lu VM; McDonald KL
    CNS Oncol; 2018 Jan; 7(1):41-50. PubMed ID: 29303363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addressing diffuse glioma as a systemic brain disease with single-cell analysis.
    Sahm F; Capper D; Jeibmann A; Habel A; Paulus W; Troost D; von Deimling A
    Arch Neurol; 2012 Apr; 69(4):523-6. PubMed ID: 22158715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Brain Tumor].
    Komori T
    Brain Nerve; 2020 Apr; 72(4):399-405. PubMed ID: 32284464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical importance of molecular markers of adult diffuse glioma.
    Molinari E; Curran OE; Grant R
    Pract Neurol; 2019 Oct; 19(5):412-416. PubMed ID: 31175262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuro-oncology: new hope for patients with gliomas.
    Deangelis LM
    Lancet Neurol; 2010 Jan; 9(1):17-8. PubMed ID: 20083029
    [No Abstract]   [Full Text] [Related]  

  • 20. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
    Chen SC; Lo CM; Wang SH; Su EC
    BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.